The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.

Estimands and their Implications on Clinical Studies

August 4, 2020

Last year, Paul Terrill, Associate Principal of Strategic Consulting at Cytel, presented an engaging webinar on the topic of Estimands. The webinar covered a range of issues from what is an estimand to how to structure early discussions on estimands. On popular demand, Paul will re-run this webinar on August 13, 2020, and add recent developments on this topic. He will share the bottom-line on estimands and discuss their implications for a trial's objectives, design, data collection, statistical analyses and conclusions. Paul will also share his guidance on managing the communication about estimands between multiple internal stakeholders, gaining internal buy-in, and ensuring that a trial’s objectives, design, conduct, analysis and interpretation are in line with the addendum. Register today by clicking on the button.

registerContinue reading this blog to understand the concept of Estimands, their role in clinical trials and the purpose of the final ICH E9(R1) addendum.

Read More

Why You Should Construct Primary Endpoints Using Bayesian Methods: Lessons from COVID-19

June 18, 2020

One of the revelations of the COVID-19 pandemic is that the flexibility and potential of Bayesian designs goes far beyond the benefits connected to informed priors. Rather a number of other benefits to Bayesian designs are sometimes under-appreciated. The importance of using Bayesian methods to choose composite endpoints, for example, particularly in longitudinal studies, can be overlooked when considering Bayesian and Frequentist options.

Cytel statisticians reflected on these benefits during a recent panel discussion.

Read More